BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

inVentiv Health (VTIV) Launches Consolidated Communications Company in Europe


8/24/2011 5:58:53 AM

BURLINGTON, Mass., Aug. 24, 2011 /PRNewswire/ -- inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced the launch of inVentiv Health Communications/Europe, a new company that brings together inVentiv's advertising, public relations, public policy, market access, medical education, marketing, branding and digital services in a unified offering serving Europe.

"All of inVentiv Health's existing communications brands, along with their many industry clients, will benefit from this enhanced model that addresses growing opportunities in healthcare. Never before has there been a better time for us to more proactively encourage and assure access to the wide range of industry talent available through our communications agencies," said Paul Meister, Chief Executive Officer of inVentiv Health.

Advertising agencies such as GSW Europe and Junction 11 will now operate as inVentiv Health Communications/Europe, while other companies, such as Chandler Chicco Companies, will continue with their brand names, but now operate under the auspices of the new "super-agency," inVentiv Health Communications/Europe.

inVentiv Health Communications/Europe will be led by Bob Chandler, Senior Vice President of Marketing and Communications of inVentiv Health and founder of Chandler Chicco Companies PRWeek's top-ranked healthcare communications agency in Europe. According to Meister, "Given Bob Chandler's track record of success within the European market, he's the ideal choice to lead our efforts."

"The power of the well-regarded assets of inVentiv Health Communications/Europe, now working in greater unison, will have a profound impact on how we tackle opportunities emerging every day in the evolving European healthcare environment," Chandler said. "Our new way of going to market is designed to facilitate a multi-disciplinary approach to driving plans and programs that reach intended target audiences with greater speed and relevancy. We believe this efficiency will generate financial savings for our clients," he further explained.

The new company's hub will be in London, where the key communications disciplines will co-locate.

About inVentiv Health

inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses, including the acquisitions of i3 and PharmaNet Development Group, Inc., into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance; and changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.

SOURCE inVentiv Health



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES